A randomized triple-blind clinical trial to compare the effectiveness of topical triamcinolone acetonate (0.1%), clobetasol propionate (0.05%), and tacrolimus orabase (0.03%) in the management of oral lichen planus

Shivakumar Sivaraman, Krishnamoorthy Santham, Aruldoss Nelson, Bijaykumar Laliytha, Pandian Azhalvel, John Hearty Deepak, Shivakumar Sivaraman, Krishnamoorthy Santham, Aruldoss Nelson, Bijaykumar Laliytha, Pandian Azhalvel, John Hearty Deepak

Abstract

Background: Oral lichen planus (OLP) is believed to result from an abnormal T-cell mediated immune response. The most useful agent in the treatment is corticosteroids. The present study will be aimed at evaluation of therapeutic efficiency of two corticosteroids triamcinolone acetonate (0.1%) and clobetasol propionate with tacrolimus orabase (0.03%), an immunomodulator in the management of OLP.

Aim: To compare the effectiveness of topical triamcinolone acetonate (0.1%), clobetasol propionate (0.05%), and tacrolimus orabase (0.03%) in the management of OLP and also to compare which has less recurrence.

Study design: The study comprises 30 patients, all were diagnosed with OLP clinically and histopathologically. They are randomly divided into three groups: Group A - triamcinolone acetonate (0.1%), Group B - clobetasol propionate (0.05%), and Group C - tacrolimus (0.03%). A formal informed consent was obtained from all of them who participated in the study.

Results and conclusion: Subjects in the Group A (triamcinolone 0.1%) and Group B (clobetasol 0.05%) show a significant reduction in lesion size than that of Group C (tacrolimus 0.03%). Group B (clobetasol 0.05%) shows a better significant reduction in lesion size than that of Group A (triamcinolone 0.1%). The overall treatment response was significant better in the Group B (clobetasol 0.05%). No recurrence was observed in any of the three groups at the end of 3 months. It is concluded that clobetasol propionate 0.05% ointment has higher efficacy when compared to triamcinolone acetonide 0.1% ointment and tacrolimus ointment 0.03% in the management of OLP. It was also inferred that triamcinolone 0.1% has better effects than tacrolimus 0.03%.

Keywords: Clobetasol propionate; oral lichen planus; tacrolimus; triamcinolone acetonate.

References

    1. Setterfield JF, Black MM, Challacombe SJ. The management of oral lichen planus. Clin Exp Dermatol. 2000;25:176–82.
    1. Vente C, Reich K, Rupprecht R, Neumann C. Erosive mucosal lichen planus: Response to topical treatment with tacrolimus. Br J Dermatol. 1999;140:338–42.
    1. Rozycki TW, Rogers RS, 3rd, Pittelkow MR, McEvoy MT, el-Azhary RA, Bruce AJ, et al. Topical tacrolimus in the treatment of symptomatic oral lichen planus: A series of 13 patients. J Am Acad Dermatol. 2002;46:27–34.
    1. Kaliakatsou F, Hodgson TA, Lewsey JD, Hegarty AM, Murphy AG, Porter SR. Management of recalcitrant ulcerative oral lichen planus with topical tacrolimus. J Am Acad Dermatol. 2002;46:35–41.
    1. Byrd JA, Davis MD, Bruce AJ, Drage LA, Rogers RS., 3rd Response of oral lichen planus to topical tacrolimus in 37 patients. Arch Dermatol. 2004;140:1508–12.
    1. Morrison L, Kratochvil FJ, 3rd, Gorman A. An open trial of topical tacrolimus for erosive oral lichen planus. J Am Acad Dermatol. 2002;47:617–20.
    1. Neville BW, Damm DD, Allen CM, Bouquets JE. Oral and Maxillofacial Pathology. 3rd ed. St. Louis, Missouri: Elsevier; 2009. pp. 54–99.
    1. Scully C, Carrozzo M. Oral mucosal disease: Lichen planus. Br J Oral Maxillofac Surg. 2008;46:15–21.
    1. Xia J, Li C, Hong Y, Yang L, Huang Y, Cheng B. Short-term clinical evaluation of intralesional triamcinolone acetonide injection for ulcerative oral lichen planus. J Oral Pathol Med. 2006;35:327–31.
    1. Porter SR, Kirby A, Olsen I, Barrett W. Immunologic aspects of dermal and oral lichen planus: A review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1997;83:358–66.
    1. Laeijendecker R, Tank B, Dekker SK, Neumann HA. A comparison of treatment of oral lichen planus with topical tacrolimus and triamcinolone acetonide ointment. Acta Derm Venereol. 2006;86:227–9.
    1. Radfar L, Wild RC, Suresh L. A comparative treatment study of topical tacrolimus and clobetasol in oral lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008;105:187–93.
    1. Lodi G, Giuliani M, Majorana A, Sardella A, Bez C, Demarosi F, et al. Lichen planus and hepatitis C virus: A multicentre study of patients with oral lesions and a systematic review. Br J Dermatol. 2004;151:1172–81.
    1. Campisi G, Giandalia G, De Caro V, Di Liberto C, Aricò P, Giannola LI. A new delivery system of clobetasol-17-propionate (lipid-loaded microspheres 0.025%) compared with a conventional formulation (lipophilic ointment in a hydrophilic phase 0.025%) in topical treatment of atrophic/erosive oral lichen planus A Phase IV, randomized, observer-blinded, parallel group clinical trial. Br J Dermatol. 2004;150:984–90.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa